WallStSmart

Abbott Laboratories (ABT)vsENvue Medical Inc. (FEED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 1650850% more annual revenue ($44.33B vs $2.69M). ABT leads profitability with a 14.7% profit margin vs -2.5%. ABT earns a higher WallStSmart Score of 51/100 (C-).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

FEED

Hold

41

out of 100

Grade: D

Growth: 7.3Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued

Intrinsic value data unavailable for FEED.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

FEED2 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
92.0%10/10

Revenue surging 92.0% year-over-year

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

FEED4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.31M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-30.5%2/10

ROE of -30.5% — below average capital efficiency

Free Cash FlowQuality
$-2.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : FEED

The strongest argument for FEED centers on Price/Book, Revenue Growth. Revenue growth of 92.0% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : FEED

The primary concerns for FEED are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

ABT profiles as a value stock while FEED is a hypergrowth play — different risk/reward profiles.

FEED carries more volatility with a beta of 2.28 — expect wider price swings.

FEED is growing revenue faster at 92.0% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (51/100 vs 41/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

ENvue Medical Inc.

HEALTHCARE · MEDICAL DEVICES · USA

ENvue Medical Inc. (FEED) is a forward-thinking healthcare technology firm committed to revolutionizing patient care management through advanced medical devices and software solutions. By harnessing innovative technology, ENvue Medical focuses on optimizing recovery processes and improving health outcomes across various clinical settings. The company's robust product pipeline, coupled with strategic collaborations, positions it well to capitalize on the growth of the healthcare industry, presenting a compelling investment opportunity for institutional investors seeking exposure to the dynamic fields of medical device innovation and digital health advancements.

Want to dig deeper into these stocks?